KJIM The Korean Journal of Internal MedicineKorean J Intern Med 1226-3303 2005-6648 The Korean Association of Internal Medicine 10.3904/kjim.2017.154 kjim-2017-154 Correspondence Response to comment on “New therapeutic agents in diabetic nephropathy” KimYaeni ParkCheol Whee Division of Nephrology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea Correspondence to Cheol Whee Park, M.D. Division of Nephrology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu, Seoul 06591, Korea Tel: +82-2-2258-6038 Fax: +82-2-599-3589 E-mail: cheolwhee@hanmail.net 5 2017 28 4 2017 32 3 570 570 12 04 2017 25 04 2017 Copyright © 2017 The Korean Association of Internal Medicine 2017 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Comment on “New therapeutic agents in diabetic nephropathy”

Thank you for your interest in the article entitled “New therapeutic agents in diabetic nephropathy” [1] and your comments on erroneous information therein. We agree that there are several errors in the article; therefore, we have made the following revisions according to your comments.

The ongoing ‘Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria’ (PRIORITY) trial is investigating the efficacy of the mineralocorticoid receptor antagonist (MRA) spironolactone, in terms of delaying the progression of early diabetic nephropathy (DN) [2]. However, concerns regarding the development of hyperkalemia in those with decreased renal function need to be addressed. The nonsteroidal MRA finerenone (BAY 94-8862) was well-tolerated in a Japanese population with DN and did not exert adverse effects on serum potassium levels or renal function [3,4]. A study of the safety of the selective aldosterone receptor antagonist MT-3995 regarding the development of hyperkalemia in subjects with DN is required [5].

We appreciate your interest in, and comments on, our article and we hope that our revisions have addressed your concerns.

No potential conflict of interest relevant to this article was reported.

 REFERENCES KimY ParkCW New therapeutic agents in diabetic nephropathy Korean J Intern Med 2017 32 11 25 LindhardtM PerssonF CurrieG Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial BMJ Open 2016 6 e010310 KatayamaS YamadaD NakayamaM A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy J Diabetes Complications 2017 31 758 765 SatoN AjiokaM YamadaT A randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and/or chronic kidney disease Circ J 2016 80 1113 1122 KolkhofP NowackC EitnerF Nonsteroidal antagonists of the mineralocorticoid receptor Curr Opin Nephrol Hypertens 2015 24 417 424